Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma

Cancer Cytopathology

Volumn 121, Issue 9, 2013, Pages 500-507

  Cai, Guoping ^a   Wong, Rebecca ^a   Chhieng, David ^a   Levy, Gillian H ^a   Gettinger, Scott N ^a   Herbst, Roy S ^a   Puchalski, Jonathan T ^a   Homer, Robert J ^a   Hui, Pei ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Anaplastic lymphoma kinase (ALK); Cytology; Epidermal growth factor receptor (EGFR); Kirsten rat sarcoma viral oncogene homolog (KRAS); Lung

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; DNA; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RAS PROTEIN; TUMOR MARKER;

ADULT; AGED; ALK GENE; ARTICLE; CANCER CYTODIAGNOSIS; CANCER RECURRENCE; CODON; CONTROLLED STUDY; EGFR GENE; EXON; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; KRAS GENE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MOLECULAR DIAGNOSIS; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VERY ELDERLY; YOUNG ADULT; ADENOCARCINOMA; ANAPLASTIC LYMPHOMA KINASE (ALK); BONE TUMOR; CYTODIAGNOSIS; CYTOLOGY; EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR); FEASIBILITY STUDY; GENETICS; KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG (KRAS); LIVER TUMOR; LUNG; LUNG TUMOR; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SOFT TISSUE TUMOR; TUMOR RECURRENCE;

ADENOCARCINOMA; ANAPLASTIC LYMPHOMA KINASE (ALK); CYTOLOGY; EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR); KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG (KRAS); LUNG;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CYTODIAGNOSIS; DNA, NEOPLASM; FEASIBILITY STUDIES; FEMALE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84887529187     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21288     Document Type: Article

References (29)

1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359: 1367-1380.
2. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin. 2011;61: 91-112.
3. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011;6: 451-458.
4. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6: 244-285.
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med. 2004;350: 2129-2139.
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304: 1497-1500.
7. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101: 13306-13311.
8. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23: 5900-5909.
9. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448: 561-566.
10. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363: 1693-1703.
11. Pirker R, Herth FJ, Kerr KM, et al; European EGFR Workshop Group. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 2010;5: 1706-1713.
12. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011;29: 2121-2127.
13. da Cunha Santos G, Saieg MA, Geddie W, Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer (Cancer Cytopathol). 2011;119: 80-91.
14. da Cunha Santos G, Liu N, Tsao MS, Kamel-Reid S, Chin K, Geddie WR. Detection of EGFR and KRAS mutations in fineneedle aspirates stored on Whatman FTA cards: is this the tool for biobanking cytological samples in the molecular era? Cancer (Cancer Cytopathol). 2010;118: 450-456.
15. Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer (Cancer Cytopathol). 2011;119: 111-117.
16. Chowdhuri SR, Xi L, Pham TH, et al. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol. 2012;25: 548-555.
17. Yung RC, Otell S, Illei P, et al. Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration. Cancer (Cancer Cytopathol). 2012;120: 185-195.
18. Emanuel JR, Damico C, Ahn S, Bautista D, Costa J. Highly sensitive nonradioactive single-strand conformational polymorphism. Detection of Ki-ras mutations. Diagn Mol Pathol. 1996;5: 260-264.
19. Cai G, Mahooti S, Lipata FM, Chhieng D, Hui P. Diagnostic value of K-ras mutation analysis for pancreaticobiliary cytology specimens with indeterminate diagnosis. Cancer (Cancer Cytopathol). 2012;120: 313-318.
20. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol. 2009;40: 1152-1158.
21. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29: 2046-2051.
22. Malapelle U, Bellevicine C, Zeppa P, Palombini L, Troncone G. Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. Diagn Cytopathol. 2011;39: 703-710.
23. van Eijk R, Licht J, Schrumpf M, et al. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One. 2011;6: e17791.
24. Smouse JH, Cibas ES, Janne PA, Joshi VA, Zou KH, Lindeman NI. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer (Cancer Cytopathol). 2009;117: 67-72.
25. Daniele L, Cassoni P, Bacillo E, et al. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol. 2009;4: 684-688.
26. Park S, Holmes-Tisch AJ, Cho EY, et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in nonsmall cell lung cancer. J Thorac Oncol. 2009;4: 809-815.
27. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res. 2009;15: 4554-4560.
28. Monaco SE, Nikiforova MN, Cieply K, Teot LA, Khalbuss WE, Dacic S. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Pathol. 2010;41: 94-102.
29. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3: 75ra26.